Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986920 · ClinicalTrials.gov registry record · Phase 1
Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
A Phase 1 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01986920 is a Phase 1 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 35 participants.
The verdict
NCT01986920, a Phase 1 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.
Interventions
- DRUG A-101 25%
- DRUG A-101 32.5%
- DRUG A-101 40%
- DRUG A-101 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-10-22 |
| Est. Completion | 2014-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01986920
The ClinicalTrials.gov registry entry for NCT01986920 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which A-101 25% is the first listed.
NCT01986920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01986920 about?
NCT01986920 is a clinical study titled "Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis". Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.
What is the current status of trial NCT01986920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2013-10-22. Estimated completion is 2014-02-25.
What interventions are being tested in trial NCT01986920?
The interventions under investigation include: A-101 25% (DRUG), A-101 32.5% (DRUG), A-101 40% (DRUG), A-101 Vehicle (DRUG).
Who is sponsoring clinical trial NCT01986920?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.